# Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer

> **NCT02842099** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TA or TAC
- **DRUG:** X

## Key facts

- **NCT ID:** NCT02842099
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2020-01
- **Final completion:** —
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842099, "Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02842099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*